We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
-2.48%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.43B
AUM Growth
+$280M
(+13%)
Cap. Flow
-$9.04M
Cap. Flow
% of AUM
-0.37%
Top 10 Holdings %
Top 10 Hldgs %
37.47%
Holding
114
New
20
Increased
14
Reduced
20
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BPMC
Blueprint Medicines
BPMC
|
+$49M |
| 2 |
LCI
Lannett Company, Inc.
LCI
|
+$46.3M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$45.7M |
| 4 |
Elevance Health
ELV
|
+$42.6M |
| 5 |
Centene
CNC
|
+$35.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DaVita
DVA
|
+$23.1M |
| 2 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$19.2M |
| 3 |
SEM
Select Medical
SEM
|
+$18.3M |
| 4 |
TSRO
TESARO, Inc.
TSRO
|
+$16.4M |
| 5 |
AET
Aetna Inc
AET
|
+$14.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 69.33% |
| 2 | Financials | 2.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $145M | 5.96% |
8,956,988
+2,522,549
| +39% | +$45.7M |
|
|
NXTM
2
DELISTED
NxStage Medical Inc.
NXTM
| $112M | 4.59% |
4,258,196
+159,021
| +4% | +$3.93M |
|
|
AVXS
3
DELISTED
AveXis, Inc. Common Stock
AVXS
| $107M | 4.39% |
2,236,701
| – | – |
|
|
PTLA
4
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $104M | 4.3% |
4,654,447
-985,280
| -17% | -$19.2M |
|
|
GWPH
5
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $104M | 4.27% |
928,192
-80,283
| -8% | -$9.66M |
|
|
AERI
6
DELISTED
Aerie Pharmaceuticals
AERI
| $69.6M | 2.86% |
1,838,829
+500,000
| +37% | +$18.9M |
|
7
Viatris
VTRS
$20.1B
| $67.4M | 2.77% |
1,766,378
+343,044
| +24% | +$12.7M |
|
|
DBVT
8
DBV Technologies
DBVT
$870M
| $61.2M | 2.52% |
174,323
| – | – |
|
9
Vanda Pharmaceuticals
VNDA
$327M
| $54.6M | 2.25% |
3,424,676
-10,900
| -0.3% | -$175K |
|
|
NVRO
10
DELISTED
NEVRO CORP.
NVRO
| $54.6M | 2.25% |
751,298
+214,943
| +40% | +$18.4M |
|
11
Xencor
XNCR
$1.3B
| $53.2M | 2.19% |
2,020,000
-190,900
| -9% | -$4.59M |
|
|
BPMC
12
DELISTED
Blueprint Medicines
BPMC
| $51.7M | 2.13% |
1,842,415
+1,626,829
| +755% | +$49M |
|
|
13
Elevance Health
ELV
$80.9B
| $45.7M | 1.88% |
+318,000
| New | +$42.6M |
|
|
LCI
14
DELISTED
Lannett Company, Inc.
LCI
| $44.3M | 1.82% |
+501,888
| New | +$46.3M |
|
|
AVDL
15
DELISTED
Avadel Pharmaceuticals
AVDL
| $42.3M | 1.74% |
4,072,809
| – | – |
|
16
Humana
HUM
$48B
| $40.4M | 1.66% |
198,000
+38,500
| +24% | +$7.34M |
|
|
UAM
17
DELISTED
Universal American Corp
UAM
| $37.6M | 1.55% |
3,774,090
-817,970
| -18% | -$7.19M |
|
|
18
Centene
CNC
$32.8B
| $34.1M | 1.4% |
+1,207,286
| New | +$35.6M |
|
|
AET
19
DELISTED
Aetna Inc
AET
| $30M | 1.23% |
242,000
-124,000
| -34% | -$14.8M |
|
|
WBA
20
DELISTED
Walgreens Boots Alliance
WBA
| $29.5M | 1.21% |
355,957
| – | – |
|
21
eHealth
EHTH
$47.3M
| $28.1M | 1.16% |
2,640,609
| – | – |
|
22
Editas Medicine
EDIT
$457M
| $27.7M | 1.14% |
1,709,400
| – | – |
|
|
LKFT
23
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
| $27.2M | 1.12% |
423,112
| – | – |
|
24
Globus Medical
GMED
$10.5B
| $25.7M | 1.06% |
+1,036,000
| New | +$23.5M |
|
|
BOLD
25
DELISTED
Audentes Therapeutics, Inc
BOLD
| $25.6M | 1.06% |
1,403,653
| – | – |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q4 2016 Portfolio in Review
As of Q4 2016, Deerfield Management held 114 positions worth $2.43B, up 13% from $2.15B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Deerfield Management's Q4 2016 filing shows 20 new, 14 increased, 20 reduced and 12 closed positions. Its largest new stake was Lannett Company, Inc.: 501,888 shares worth $44.3M. The largest sale was DaVita, an estimated $23.1M.
By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 70% a quarter earlier, followed by Financials.
- Deerfield Management's largest Q4 2016 buy was Lannett Company, Inc.: 501,888 shares worth $44.3M.
- Deerfield Management added most to Blueprint Medicines in Q4 2016, an estimated $49M increase.
- Deerfield Management's biggest Q4 2016 reduction was Portola Pharmaceuticals, Inc., cutting an estimated $19.2M.
- Deerfield Management fully exited DaVita in Q4 2016, selling an estimated $23.1M.
- Deerfield Management's ten largest holdings make up 37% of its $2.43B portfolio in Q4 2016.
- Deerfield Management opened 20 new positions and closed 12 in Q4 2016.
- Deerfield Management's portfolio value rose 13% quarter-over-quarter to $2.43B.
Based on Deerfield Management's 13F filing for Q4 2016, filed 14 Feb 2017.